When a founder gets their first term sheet, the eye goes straight to one number: the valuation. That is understandable and largely a mistake. The economic and control terms buried below the valuation often matter more to what a founder actually walks away with than the headline number does. A high valuation with punishing terms can be worth far less than a lower valuation on clean ones. Here is what actually matters in a biotech term sheet.
The economic terms
- Valuation (pre-money and post-money). The pre-money valuation plus the investment equals the post-money, and your ownership is your shares divided by the post-money total. Be clear which number is being quoted, because the difference is real money.
- Liquidation preference. This determines who gets paid first in an exit, and it is arguably the most consequential economic term. A standard one times non-participating preference means the investor gets their money back or converts to common and shares proportionally, whichever is better, which is founder-friendly and market standard. A participating preference means they get their money back and share in the remainder, which can badly reduce founder proceeds. Multiples above one times are aggressive. In a modest exit, these terms can determine whether founders receive anything at all.
- Option pool. Watch whether the pool is created pre-money, which effectively dilutes existing shareholders rather than the new investor, a subtle but significant point that is routinely negotiated.
- Anti-dilution. This protects investors if you later raise at a lower price. Broad-based weighted average is standard and reasonable; full ratchet is punitive and worth resisting.
The control terms
Who decides what may matter as much as who owns what. The board composition determines governance and, ultimately, whether you keep your job, so the balance between founders, investors, and independent directors is a critical negotiation. Protective provisions are the list of actions requiring investor consent, such as selling the company, raising more money, or changing the business, and while some are entirely reasonable, an overly broad list can leave you unable to act without your investors’ permission. Information rights and reporting obligations are normal. And founder vesting, which often surprises first-timers, means your own shares vest over time, protecting the company if a founder leaves early.
Terms that matter especially in biotech
Biotech has its own wrinkles. Tranched financing is common, where the investment is released in stages tied to hitting specific milestones, such as a data readout. This can be entirely sensible, but the milestones must be realistic and clearly defined, because a tranche you cannot unlock leaves you with a fraction of the money you thought you had raised and a fundraise you must restart from weakness. Pay-to-play provisions, which penalize investors who do not participate in future rounds, matter in a sector where companies frequently need multiple rounds. And because biotech rounds are large and syndicated, the quality and reputation of your lead investor, and their ability to support future rounds, is itself a term worth weighing heavily.
What founders should actually negotiate
Prioritize. The terms most worth fighting for are usually the liquidation preference (insist on one times non-participating if you can), the board composition, the scope of protective provisions, the option pool treatment, and, if tranched, the realism and clarity of the milestones. Valuation matters, but trading a slightly lower valuation for clean terms is very often the better deal, and experienced founders know it. Get a lawyer who does this constantly, because the cost of good counsel here is trivial against the cost of a bad term. And remember that a term sheet is the beginning of a long relationship, so how an investor negotiates tells you a great deal about what they will be like on your board for the next decade.
The bottom line
A term sheet is not a valuation with paperwork attached; it is a set of economic and control provisions that will shape your company’s future and determine what you personally receive if it succeeds. Look past the headline number to the liquidation preference, the board, the protective provisions, and, in biotech especially, the structure and realism of any milestone tranches. Negotiate the terms that genuinely matter, accept the ones that are market standard, and get experienced counsel, because the details you gloss over at signing are exactly the ones that will matter most at the exit.
The relationship behind the terms
A point that experienced founders make repeatedly, and first-time founders often learn the hard way, is that a term sheet is the opening of a decade-long relationship, and the character of the investor matters at least as much as the terms they offer. You will be in the room with these people through your worst moments, a failed trial, a missed milestone, a financing that will not close, and how they behave then will shape your company’s fate. This has practical implications for how you evaluate an offer. Do reference diligence on the investor as seriously as they do it on you: speak to founders they have backed, including, and especially, founders whose companies struggled, because how an investor behaves when things go badly is the most revealing information available and is exactly what you will not learn from their website. Ask how they have handled down rounds, pipeline failures, and management changes. Consider whether they have the capital and the appetite to support you in future rounds, which matters enormously in a capital-hungry industry where an investor who cannot follow on leaves you exposed. And pay attention to how they negotiate the term sheet itself, because a party who is aggressive, opaque, or ungenerous over small points during courtship is unlikely to become more reasonable once they hold a board seat. A slightly worse term sheet from an investor you trust and who will stand behind you is frequently a better deal than a better term sheet from one who will not, and that judgment, more than any individual clause, is often what determines whether a company survives its hard years.
The bottom line, restated
A term sheet is a set of economic and control provisions that will govern your company for years, not a valuation with paperwork attached. Prioritize the liquidation preference, the board, the protective provisions, the option pool, and the realism of any milestone tranches. Trade valuation for clean terms when you can, get counsel who does this constantly, and do diligence on the investor as seriously as they do it on you, because you are choosing a partner for the hardest decade of your professional life, and the clauses you skim past today are precisely the ones that will matter most at the end.
Reference the investor as hard as they reference you
Before you sign, speak to founders your prospective investor has backed, and make sure at least one of them ran a company that struggled, because that is where you learn who an investor really is. Did they support the company through the hard period or head for the exit? Did they behave well in a down round? Did they help, or merely opine? An hour of these conversations is the highest-value diligence available to a founder, and it is astonishing how rarely it is done given how much of your future depends on the answer.
Understand your own cap table math
Before you negotiate anything, model what the proposed terms actually mean for your ownership and your proceeds across a range of exit scenarios, including modest ones. Founders routinely accept terms whose consequences they have not calculated, and are then startled at exit to find how much of the value went elsewhere. Run the numbers on a small exit, a medium one, and a large one, and see how the liquidation preference and the option pool actually behave. That exercise takes an afternoon and will change how you negotiate, because the arithmetic is far more sobering than the term sheet’s language suggests.
For the investors behind these term sheets, browse the BioMed Nexus venture capital directory, and see our guides on how to pitch a biotech VC and raising a biotech Series A.
Frequently asked questions
What is the most important term in a term sheet?
The liquidation preference is arguably the most consequential economic term, because it determines who gets paid first in an exit. A one times non-participating preference is founder-friendly and market standard, while a participating preference means investors get their money back and share in the remainder, which can badly reduce founder proceeds in a modest exit.
What is tranched financing in biotech?
Tranched financing releases the investment in stages tied to hitting specific milestones, such as a clinical data readout. It is common in biotech and can be sensible, but the milestones must be realistic and clearly defined, because a tranche you cannot unlock leaves you with a fraction of the money you expected and forces you to restart fundraising from a position of weakness.
Should founders negotiate valuation or terms?
Terms often matter more. A high valuation with punishing terms can be worth far less than a lower valuation on clean ones. Prioritize the liquidation preference, board composition, scope of protective provisions, option pool treatment, and the realism of any milestone tranches. Trading a slightly lower valuation for clean terms is frequently the better deal.
